News of the company Basilea Pharmaceutica

<<��

�1�� 2��

Article 1 to 10 out of 15 concerning Basilea Pharmaceutica AG

Basilea's Ceftobiprole shows high cure rates in patients hospitalized with community-acquired pneumonia (05/23/2008)
Basilea Pharmaceutica Ltd. highlights the presentation of positive phase III results on ceftobiprole in the treatment of community-acquired pneumonia (CAP) requiring hospitalization at the International Conference of the American Thoracic Society ...

more information
�
Basilea opens new phase III study in special patient populations for its broad-spectrum antifungal isavuconazole (04/16/2008)
Basilea Pharmaceutica Ltd. announced that it has opened an additional phase III study to evaluate the efficacy and safety of isavuconazole in treating serious and life-threatening invasive fungal infections. Isavuconazole's breadth of spectrum in ...

more information
�
Basilea Focuses on Commercialization (12/17/2007)
Basilea Pharmaceutica Ltd. announced a new management structure reflecting the company's high priority on commercializing its pre-registrations drugs.Basilea has two investigatory drugs for high medical need currently undergoing regulatory review ...

more information
�
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia (10/10/2007)
Basilea Pharmaceutica Ltd. announced that the ceftobiprole phase III top-line study results in hospital-acquired pneumonia (HAP) met the primary endpoint of non-inferiority versus combination therapy of ceftazidime plus linezolid. Ceftobiprole is ...

more information
�
Basilea: Submission of marketing authorization application for Alitretinoin to Swiss regulatory authority (10/02/2007)
Basilea Pharmaceutica Ltd. announced the submission of a marketing authorization application to Swissmedic for its investigational drug alitretinoin. The submission supports the proposed use of oral alitretinoin in severe refractory chronic hand ...

more information
�
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole (06/19/2007)
Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission ...

more information
�
Swiss Regulatory Authority Grants Accelerated Assessment of Planned Market Authorization Application for Ceftobiprole (06/01/2007)
Basilea Pharmaceutica Ltd. announced that Swissmedic granted Janssen-Cilag AG, a Johnson & Johnson company, accelerated assessment of the planned market authorization application ("Beschleunigtes Zulassungsverfahren") for ceftobiprole for the ...

more information
�
Basilea submits New Drug Application for anti-MRSA Broad-spectrum Cephalosporin to U.S. Authorities (05/22/2007)
Basilea Pharmaceutica Ltd. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ceftobiprole by its co-development partner Johnson & Johnson Pharmaceutical Research and Development, L.L.C. This ...

more information
�
Basilea Reports Positive Phase III Results for Alitretinoin (02/20/2007)
Basilea Pharmaceutica Ltd. announced that its placebo-controlled pivotal phase III BACH trial (Benefit of Alitretinoin in Chronic Hand dermatitis) successfully met its primary objective. Alitretinoin was effective in patients suffering from severe ...

more information
�
Basilea Announces Start of Phase III Program for Isavuconazole (12/20/2006)
Basilea Pharmaceutica Ltd. announced the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557) in patients with invasive systemic fungal infections caused by yeasts and molds. The global trial program for ...

more information
�

<<��

�1�� 2��

Current News RSS

Basilea Pharmaceutica AG
Basel, Switzerland

Current NewsRSS

Basilea Pharmaceutica AGBasel, Switzerland

Current News RSS

Basilea Pharmaceutica AG
Basel, Switzerland